ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 8.8% in March

ADMA Biologics, Inc. (NASDAQ:ADMA) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 7,290,000 shares, a decrease of 8.8% from the March 15th total of 7,990,000 shares. Based on an average daily trading volume, of 2,750,000 shares, the short-interest ratio is presently 2.7 days.

ADMA Biologics Trading Up 3.0 %

Shares of NASDAQ:ADMA opened at $6.16 on Wednesday. The company has a market capitalization of $1.41 billion, a P/E ratio of -47.62 and a beta of 0.46. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $6.76. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. The business’s 50 day simple moving average is $5.88 and its 200 day simple moving average is $4.71.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The business had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. On average, research analysts anticipate that ADMA Biologics will post 0.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ADMA. Mizuho upped their target price on ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and issued a $7.50 target price (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. Finally, Cantor Fitzgerald upped their target price on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ADMA Biologics currently has an average rating of “Buy” and a consensus target price of $7.88.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 407,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $6.21, for a total value of $2,527,470.00. Following the sale, the director now owns 3,208,671 shares in the company, valued at $19,925,846.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 639,895 shares of company stock worth $3,927,169 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in ADMA Biologics during the second quarter worth $34,000. Envestnet Asset Management Inc. bought a new stake in ADMA Biologics during the first quarter worth $35,000. Price T Rowe Associates Inc. MD bought a new stake in ADMA Biologics during the second quarter worth $35,000. Stephens Consulting LLC bought a new stake in ADMA Biologics during the third quarter worth $36,000. Finally, Cerity Partners LLC bought a new stake in ADMA Biologics during the second quarter worth $37,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.